Research Article
Expression of Pentose Phosphate Pathway-Related Proteins in Breast Cancer
Table 2
Clinicopathologic characteristics of patients according to breast cancer phenotype.
| | Parameter | Total
()
(%) | Luminal A
()
(%) | Luminal B
()
(%) | HER-2
()
(%) | TNBC
()
(%) | value |
| | Age (years) | | | | | | 0.299 | | ≤50 | 202 (58.0) | 94 (58.0) | 55 (65.5) | 13 (48.1) | 40 (53.3) | | | >50 | 146 (42.0) | 68 (42.0) | 29 (34.5) | 14 (51.9) | 35 (46.7) | | | Histologic grade | | | | | | <0.001 | | I/II | 242 (69.5) | 147 (90.7) | 53 (63.1) | 12 (44.4) | 30 (40.0) | | | III | 106 (30.5) | 15 (9.3) | 31 (36.9) | 15 (55.6) | 45 (60.0) | | | Tumor stage | | | | | | 0.068 | | T1 | 182 (52.3) | 96 (59.3) | 42 (50.0) | 13 (48.1) | 31 (41.3) | | | T2/T3 | 166 (47.7) | 66 (40.7) | 42 (50.0) | 14 (51.9) | 44 (58.7) | | | Nodal metastasis | | | | | | 0.676 | | Absent | 208 (59.8) | 94 (58.0) | 48 (57.1) | 17 (63.0) | 49 (65.3) | | | Present | 140 (40.2) | 68 (42.0) | 36 (42.9) | 10 (37.0) | 26 (34.7) | | | Estrogen receptor status | | | | | | <0.001 | | Negative | 107 (30.7) | 2 (1.2) | 3 (3.6) | 27 (100.0) | 75 (100.0) | | | Positive | 241 (69.3) | 160 (98.8) | 81 (96.4) | 0 (0.0) | 0 (0.0) | | | Progesterone receptor status | | | | | | <0.001 | | Negative | 149 (42.8) | 20 (12.3) | 27 (32.1) | 27 (100.0) | 75 (100.0) | | | Positive | 199 (57.2) | 142 (87.7) | 57 (67.9) | 0 (0.0) | 0 (0.0) | | | HER-2 status | | | | | | <0.001 | | Negative | 280 (80.5) | 162 (100.0) | 43 (51.2) | 0 (0.0) | 75 (100.0) | | | Positive | 68 (19.5) | 0 (0.0) | 41 (48.8) | 27 (100.0) | 0 (0.0) | | | Ki-67 LI (%) | | | | | | <0.001 | | ≤14 | 213 (61.2) | 162 (100.0) | 24 (28.6) | 13 (48.1) | 14 (18.7) | | | >14 | 135 (38.8) | 0 (0.0) | 60 (71.4) | 14 (51.9) | 61 (81.3) | |
|
|
TNBC: triple-negative breast cancer.
|
